Globe Life
GL
$172.67
-0.07%
Globe Life Inc. is an insurance holding company that provides life insurance, supplemental health insurance, and annuities to a broad customer base, operating through three reportable segments: life insurance, supplemental health insurance, and investments. As a well-established player in the U.S. life and supplemental health insurance market, Globe Life distinguishes itself with a focus on middle-income consumers and a diversified distribution network. The current investor narrative centers on the company's consistent revenue growth, robust profitability, and shareholder returns through dividends and buybacks, while also monitoring the impact of interest rates on investment yields and the competitive landscape. Recent financial performance shows steady top-line expansion and strong cash generation, reinforcing its position as a stable income-oriented investment.…
GL
Globe Life
$172.67
Investment Opinion: Should I buy GL Today?
Rating: Buy. Globe Life offers a compelling value proposition with a trailing PE of 9.78x, well below the industry average, and a PEG of 0.51 indicating undervaluation. The company's consistent revenue growth of 5.35% YoY, strong margins (net margin 19.36%), and robust free cash flow of $1.23B support a positive outlook. Analyst consensus is bullish with an average target of $193.91, implying 12.2% upside, and the high target of $225 suggests 30.2% potential. The stock's low beta of 0.47 provides defensive characteristics, making it suitable for income-oriented investors seeking stability.
Sign up to view all
GL 12-Month Price Forecast
The AI assessment is bullish on Globe Life, driven by its attractive valuation and strong fundamentals. The stock's low PE and PEG suggest it is undervalued relative to its growth, and its consistent revenue growth and high margins provide a solid foundation. However, the medium confidence reflects uncertainties around interest rates and competitive dynamics. If the company can maintain its growth trajectory and the market re-rates the stock, there is significant upside potential. Key developments to watch include interest rate movements and quarterly earnings, which could either validate or challenge the bullish stance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Globe Life's 12-month outlook, with a consensus price target around $193.91 and implied upside of +12.3% versus the current price.
Average Target
$193.91
0 analysts
Implied Upside
+12.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$166 - $225
Analyst target range
Globe Life is covered by 11 analysts, with a consensus recommendation leaning bullish, as evidenced by recent actions from firms like Piper Sandler (Overweight), Morgan Stanley (Overweight), and TD Cowen (Buy). The average target price is $193.91, implying an upside of approximately 12.2% from the current price of $172.79. The target range spans from a low of $166.00 to a high of $225.00, with the high target suggesting significant upside potential of 30.2%, likely assuming continued strong performance and multiple expansion. The low target of $166.00 implies a downside of -3.9%, reflecting potential risks such as margin compression or adverse regulatory changes. The relatively wide spread between the low and high targets indicates moderate uncertainty, but the overall sentiment is positive, with no recent downgrades and several reaffirmations of positive ratings. This suggests analysts have confidence in Globe Life's ability to deliver steady growth and shareholder returns.
Bulls vs Bears: GL Investment Factors
Globe Life presents a compelling value investment with strong fundamentals, including a low PE of 9.78x, high margins, and robust cash flow. The bull case is supported by undervaluation metrics (PEG 0.51) and positive analyst sentiment, while the bear case highlights interest rate sensitivity and moderate growth. Currently, the bull side has stronger evidence due to the stock's attractive valuation and consistent performance. The key tension is whether the market will re-rate the stock higher as growth continues, or if external factors like rates and competition will keep the multiple compressed. If revenue growth accelerates or interest rates rise favorably, the stock could see significant upside; otherwise, it may remain a steady but undervalued income play.
Bullish
- Undervalued with PEG of 0.51: The PEG ratio of 0.51 indicates the stock is trading well below its growth rate, suggesting undervaluation. With a trailing PE of 9.78x versus the industry average of 10-15x, the stock offers a compelling value proposition for investors seeking both growth and income.
- Strong profitability metrics: Globe Life boasts a net margin of 19.36% and an operating margin of 24.38%, reflecting efficient cost management and strong underwriting discipline. ROE of 19.43% and ROA of 3.36% demonstrate effective capital utilization, supporting sustainable earnings growth.
- Consistent revenue growth: Revenue grew 5.35% year-over-year in Q1 2026, with sequential increases from $1,480.4M to $1,559.6M. This steady top-line expansion is driven by both life and health segments, providing a solid foundation for future earnings.
- Healthy balance sheet and cash flow: With a debt-to-equity ratio of 0.44 and current ratio of 9.66, the company maintains strong liquidity and moderate leverage. Free cash flow of $1.23B TTM supports dividend payments and share buybacks, with a low payout ratio of 7.41% leaving ample room for increases.
Bearish
- Sensitivity to interest rates: As an insurance company, Globe Life's investment yields are tied to interest rates. A prolonged low-rate environment could compress investment income, impacting overall profitability. The company's beta of 0.47 indicates lower market correlation, but rate changes remain a key risk.
- Moderate growth compared to tech: Revenue growth of 5.35% is modest relative to high-growth sectors, which may limit multiple expansion. The stock's PE of 9.78x, while undervalued, could remain low if growth doesn't accelerate, potentially capping upside.
- Recent price volatility: The stock experienced a -11.04% max drawdown and a -3.83% 1-month price change, indicating short-term volatility. The recent drop from $191.55 high to $172.79 suggests profit-taking or sector rotation, which could persist.
- Regulatory and competitive pressures: The insurance industry faces evolving regulations and competitive threats from fintech and insurtech players. Any adverse regulatory changes or increased competition could pressure margins and market share, impacting long-term growth.
GL Technical Analysis
Globe Life's stock has demonstrated a sustained uptrend over the past year, with a 1-year price change of +23.02%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $172.79 sits at approximately 90% of its 52-week range (low: $127.85, high: $191.55), indicating the stock is trading near the upper end of its range, which typically reflects strong momentum but also potential overextension. The 6-month price change of +18.95% further confirms the bullish trend, with the stock having recovered from a drawdown of -11.04% earlier in the period.
Beta
0.47
0.47x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$128-$192
Price range past year
Annual Return
+23.4%
Cumulative gain past year
| Period | GL Return | S&P 500 |
|---|---|---|
| 1m | -5.3% | +2.7% |
| 3m | +14.3% | +1.0% |
| 6m | +19.3% | +12.0% |
| 1y | +23.4% | +18.9% |
| ytd | +24.7% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GL Fundamental Analysis
Globe Life's revenue has been growing steadily, with the most recent quarter (Q1 2026) reporting revenue of $1,559.6 million, a 5.35% year-over-year increase, up from $1,480.4 million in Q1 2025. This growth is driven by both the life insurance segment ($853.2 million) and the health segment ($416.9 million), with the life segment being the larger contributor. The company has maintained consistent revenue growth over the past several quarters, with Q4 2025 revenue of $1,523.9 million and Q3 2025 revenue of $1,513.0 million, indicating a stable and slightly accelerating trajectory. The net income for Q1 2026 was $270.5 million, with a net margin of 17.35%, reflecting strong profitability. Gross margin for the quarter was 49.37%, which is robust for the insurance industry, and the operating margin stood at 23.60%, demonstrating efficient cost management. The company's return on equity (ROE) is 19.43%, and return on assets (ROA) is 3.36%, both indicating effective use of capital. Globe Life maintains a healthy balance sheet with a debt-to-equity ratio of 0.44, and its current ratio of 9.66 suggests ample liquidity. Free cash flow for the trailing twelve months is $1,229.8 million, providing strong cash generation to support dividends and share buybacks. The company's payout ratio is a modest 7.41%, leaving substantial room for future dividend increases or reinvestment.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+5.3%
YoY Comparison
Gross Margin
49.4%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GL Overvalued?
Given Globe Life's positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 9.78x, while the forward PE is 10.46x, indicating that the market expects slightly lower earnings growth in the near term. The PEG ratio of 0.51 suggests the stock is undervalued relative to its growth rate, as a PEG below 1 typically indicates undervaluation. Compared to the industry average, Globe Life's PE of 9.78x is at a discount to the broader market and likely below the insurance sector average, which typically trades in the 10-15x range. This discount may be justified by the company's moderate growth and sensitivity to interest rates, but it also presents a potential value opportunity. Historically, Globe Life's PE has ranged from approximately 7.3x to 15.2x over the past few years, with the current level near the lower end of that range, suggesting the stock is trading at a historically attractive valuation. The price-to-book ratio of 1.89x is also below the historical average of around 2.0x, further supporting the value case.
PE
9.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Globe Life's financial health is generally strong, but it carries moderate debt with a debt-to-equity ratio of 0.44, which could become a concern if interest rates rise sharply, increasing interest expenses. The company's net margin of 19.36% is robust, yet it relies heavily on investment income, which is sensitive to rate fluctuations. Revenue concentration in the life insurance segment (54.7% of Q1 revenue) poses a risk if that market faces disruption. Additionally, the payout ratio of 7.41% is low, but any significant dividend cut would signal distress. Cash flow generation is solid at $1.23B TTM, providing a buffer, but a prolonged low-rate environment could pressure investment yields and overall profitability.
FAQ
The key risks include: 1) Interest rate sensitivity, as lower rates can compress investment yields and reduce profitability. 2) Competitive pressures from insurtech companies that could disrupt traditional distribution. 3) Regulatory changes that may increase compliance costs. 4) Economic downturns that could lead to higher policy lapses, especially among middle-income customers. The most severe risk is a prolonged low-rate environment, which could significantly impact earnings. However, the company's strong balance sheet and cash flow mitigate some of these risks.
The 12-month forecast for GL is positive, with a base case target of $193.91 (12.2% upside) and a bull case target of $225 (30.2% upside). The bear case target is $166 (-3.9% downside). The base case, with a 50% probability, assumes steady growth and stable margins. The bull case, at 30% probability, requires favorable interest rates and accelerating growth. The bear case, at 20% probability, involves adverse economic conditions. Overall, the most likely scenario is moderate appreciation, making GL a favorable investment.
GL is undervalued based on multiple metrics. Its trailing PE of 9.78x is below the industry average of 10-15x and its historical range of 7.3-15.2x. The PEG ratio of 0.51 is well below 1, indicating the stock is cheap relative to its growth rate. The price-to-book ratio of 1.89x is also below the historical average of 2.0x. This suggests the market is pricing in lower growth expectations, but the company's consistent revenue growth and high margins may warrant a higher multiple. Overall, the stock offers a value opportunity.
Yes, GL appears to be a good buy for value-oriented investors. The stock trades at a trailing PE of 9.78x, below the industry average of 10-15x, and has a PEG of 0.51, indicating undervaluation. Analyst targets suggest a 12.2% upside to the average of $193.91, with a high target of $225. The main downside risk is a -3.9% decline to the low target of $166, but the company's strong fundamentals and cash flow provide a margin of safety. For investors seeking a stable, income-generating stock with growth potential, GL is a solid choice.
GL is more suitable for long-term investment due to its stable business model and low beta of 0.47, which reduces volatility. The company's consistent revenue growth, high margins, and strong cash flow support long-term value creation. While short-term traders might find opportunities in its price swings, the stock's defensive characteristics and dividend yield of 0.76% make it ideal for buy-and-hold investors. A minimum holding period of 3-5 years is recommended to fully realize the benefits of compounding and potential multiple expansion.